News

Keytruda Can Trigger Blood Disorders Including AIHA, Rare Case Suggests

Treatment with the anti-PD-1 targeted checkpoint inhibitor Keytruda (pembrolizumab) was found to trigger autoimmune hemolytic anemia (AIHA) in a man with non-small cell lung cancer (NSCLC). The case was described in the study, “Pembrolizumab-induced Autoimmune Hemolytic Anemia and Hemophagocytic Lymphohistiocytosis in Non-small Cell Lung…

Apellis, SFJ Partnering on APL-2 Development for Treatment of CAD, wAIHA

Apellis Pharmaceuticals and SFJ Pharmaceuticals are now collaborating on the development of investigational therapy APL-2 as a treatment for cold agglutinin disease (CAD) and warm antibody hemolytic anemia (wAIHA). This follows the announcement of a newly established partnership to support the clinical program of APL-2 for the treatment…